Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 19/20 | 1.00 |
| ▸ | CDK1 | P06493 | 19/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 19/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 19/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 17/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 17/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 3/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 2/20 | 1.00 |
| ▸ | CDK9 | P50750 | 2/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CDC7 | O00311 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kenpaullone SCHEMBL30789744 | 1.00 | GSK3B (1.00) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| Kenpaullone SCHEMBL29366756 | 1.00 | GSK3B (1.00) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL5688213 | 0.90 | CCNB2 (1.00) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL30319776 | 0.90 | CCNB2 (1.00) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL5688155 | 0.90 | GSK3B (1.00) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL30319757 | 0.90 | GSK3B (1.00) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL5689156 | 0.86 | GSK3B (1.00) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL30319766 | 0.86 | GSK3B (1.00) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| Paullone SCHEMBL3178594 | 0.85 | CCNB2 (1.00) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| Paullone SCHEMBL29407267 | 0.85 | CCNB2 (1.00) | GSK3BCCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50313-E1 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | CELLATOZ THERAPEUTICS, INC. (KR) | 2025-02-25 | — | — | US | claimed |
| US-20240269129-A1 | GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS FOR TREATING CTNNB1 SYNDROME | THE BROAD INSTITUTE, INC. | 2024-08-15 | — | — | US | claimed |
| US-20240091254-A1 | WNT AGONISTS FOR PREVENTION OF CANCER | Stichting Amsterdam UMC (NL) | 2024-03-21 | — | — | US | claimed |
| CN-116438295-A | Methods and compositions for culturing pluripotent cell suspensions | 生命技术公司 | 2023-07-14 | — | — | CN | claimed |
| EP-4168536-A1 | METHODS AND COMPOSITIONS FOR CULTIVATING PLURIPOTENT CELL SUSPENSIONS | Life Technologies Corporation (US) | 2023-04-26 | — | — | EP | claimed |
| EP-3702445-B1 | NOVEL MUSCULOSKELETAL STEM CELL | CELLATOZ THERAPEUTICS INC (KR) | 2022-12-07 | — | — | EP | claimed |
| US-20220281930-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | DUKE UNIVERSITY (US) | 2022-09-08 | — | — | US | claimed |
| EP-4017873-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | Duke University (US) | 2022-06-29 | — | — | EP | claimed |
| US-20210395698-A1 | METHODS AND COMPOSITIONS FOR CULTIVATING PLURIPOTENT CELL SUSPENSIONS | Life Technologies Corporation | 2021-12-23 | — | — | US | claimed |
| US-20200399602-A1 | Method for Differentiation of Human Pluripotent Stem Cell Lines in Suspension Culture | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-24 | — | — | US | claimed |
| WO-2013142817-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2013-09-26 | — | — | WO | claimed |
| US-20130236436-A1 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USNIG THEM | ZHANG KANG (US) | 2013-09-12 | — | — | US | claimed |
| US-20130095567-A1 | DIRECTED DIFFERENTIATION AND MATURATION OF PLURIPOTENT CELLS INTO HEPATOCYTE LIKE CELLS BY MODULATION OF WNT-SIGNALLING PATHWAY | CELLARTIS AB (SE) | 2013-04-18 | — | — | US | claimed |
| EP-2550355-A1 | DIRECTED DIFFERENTIATION AND MATURATION OF PLURIPOTENT CELLS INTO HEPATOCYTE LIKE CELLS BY MODULATION OF WNT-SIGNALLING PATHWAY | Cellartis AB (SE) | 2013-01-30 | — | — | EP | claimed |
| EP-2494865-A2 | GUT FLORA-DERIVED EXTRACELLULAR VESICLES, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE, AND CANDIDATE DRUG AND FOR DIAGNOSIS USING SAME | Aeon Medix Inc. (KR) | 2012-09-05 | — | — | EP | claimed |
| WO-2012034101-A2 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | WO | claimed |
| WO-2011116930-A1 | DIRECTED DIFFERENTIATION AND MATURATION OF PLURIPOTENT CELLS INTO HEPATOCYTE LIKE CELLS BY MODULATION OF WNT-SIGNALLING PATHWAY | CELLARTIS AB (SE) | 2011-09-29 | — | — | WO | claimed |
| US-20060217368-A1 | Drug for nerve regeneration | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-28 | — | — | US | claimed |
| EP-1645286-A1 | DRUG FOR NERVE REGENERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-12 | — | — | EP | claimed |
| US-20020042412-A1 | Fused azepinone cyclin dependent kinase inhibitors | HEALTH AND HUMAN SERVICES, DEPARTMENT OF, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE, THE | 2002-04-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217368-A1 | Drug for nerve regeneration | GSK3A, BDNF, GSK3B | GSK3B 3/4885CCNB2 2747/4885CDK1 435/4885 |
| US-20240269129-A1 | GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS FOR TREATING CTNNB1 SYNDROME | GSK3B, GSK3A, CTNNB1 | GSK3B 1/4885CCNB2 1365/4885CDK1 296/4885 |
| US-20020042412-A1 | Fused azepinone cyclin dependent kinase inhibitors | CCNI, CCNK, CDKN1A | GSK3B 4154/4885CCNB2 61/4885CDK1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.